IRCT20191218045795N2 IRCT 2020-04-04 Sanandaj University of Medical Sciences The effect of Deluxitine on the negative symptoms of schizophrenia The effects of Duloxetine adjuantive treatment on Negative Symptoms of Schizophrenia 2019-09-23 anticipated 44 Complete https://irct.ir/trial/44334 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Single, Purpose: Treatment, Randomization description: The patients will be randomly assigned to the intervention and control groups using block randomization The patients will be randomly assigned to the intervention and control groups using block randomization Arrangement of the randomization process: 1) Determining the volume of each block (quadruple blocks) 2) Preparing the list of the blocks and assigning a number (between 1 and 6 ) to each of them 3)Choosing random numbers between 1 and 6 4) Defining the treatment assignment list, Blinding description: The physician who will examine the patients will not be aware of the intervention. Therefore, the trial will be run as double blind. N/A Negative symptom. Intervention 1: Intervention group: Deloxitin powder, manufactured by Dana Gostar Pharmaceuticals and weighed with 10 mg precision scales, is poured into the empty capsules. Patients receive 30 mg of deluxitine and antipsychotic capsules daily for one week, and from the second week, they are given two capsules of 60 mg daily, lasting for 7 weeks. Intervention 2: Control group: The control group received placebo, which is completely uniform, colorless and odorless with the drug. Patients were given placebo for one week and two capsules for the second week and continued for 7 weeks. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is The study has not been completed yet